Table 2.
Factors associated with improvement in retinal nonperfusion after intravitreal aflibercept injections
| Univariate | Multivariate | |||
| OR | P value | OR | P value | |
| Demographics | ||||
| Age, years | 0.921 | 0.138 | ||
| Female sex | 0.525 | 0.417 | ||
| Hypertension | 0.292 | 0.092 | ||
| Duration of diabetes, years | 0.938 | 0.355 | ||
| HbA1C, % | 1.213 | 0.474 | ||
| Insulin and OHA, N (vs OHA only) | 2.602 | 0.955 | ||
| Ocular characteristics | ||||
| BCVA, logMAR | 1.618 | 0.832 | ||
| Diabetic retinopathy severity (vs early PDR) | ||||
| Moderate NPDR | 18.000 | 0.074 | 20.904 | 0.071 |
| Severe NPDR | 15.000 | 0.035 | 19.119 | 0.025 |
| Very severe NPDR | 5.000 | 0.177 | 3.244 | 0.083 |
| Pseudophakic lens status | 1.021 | 0.789 | ||
| Refractive error, D | 1.413 | 0.525 | ||
| Intraocular pressure, mm Hg | 0.650 | 0.822 | ||
| Presence of PPL | 0.521 | 0.360 | ||
| Nonperfusion index (per 0.1) | 1.111 | 0.031 | ||
| Leakage index (per 0.1) | 12.063 | 0.005 | 15.152 | 0.020 |
| Central retinal thickness, μm | 1.955 | 0.652 | ||
| Subfoveal choroidal thickness, μm | 1.770 | 0.240 | ||
BCVA, best-corrected visual acuity; NPDR, nonproliferative diabetic retinopathy; OHA, oral hypoglycemic agents; PDR, proliferative diabetic retinopathy; PPL, predominantly peripheral lesion.